Literature DB >> 17021269

Role of parathyroid hormone in the downregulation of liver cytochrome P450 in chronic renal failure.

Josée Michaud1, Judith Naud, Jérôme Chouinard, François Désy, Francois A Leblond, Karine Desbiens, Alain Bonnardeaux, Vincent Pichette.   

Abstract

Chronic renal failure (CRF) is associated with a decrease in drug metabolism secondary to a decrease in liver cytochrome P450 (P450). The predominant theory to explain this decrease is the presence of factors in the blood of uremic patients. This study tested the hypothesis that parathyroid hormone (PTH) could be this factor. The objectives of this study were to determine (1) the role of PTH in the downregulation of hepatocyte P450 induced by rat uremic serum, (2) the role of PTH in the downregulation of liver P450 in rats with CRF, and (3) the effects of PTH on P450 in hepatocytes. For this purpose, (1) hepatocytes were incubated with serum from rat with CRF that was depleted with anti-PTH antibodies or with serum from parathyroidectomized (CRF-PTX) rat with CRF, (2) the effect of PTX on liver P450 was evaluated in rats with CRF, and (3) the effects of PTH on P450 in hepatocytes were determined. The depletion of PTH from CRF serum completely reversed the downregulating effect of CRF serum on P450 in hepatocytes. Addition of PTH (10(-9) M) to depleted CRF serum induced a decrease in P450 similar to nondepleted CRF serum. The serum of CRF-PTX rats had no effect on P450 in hepatocytes compared with CRF serum. Adding PTH to CRF-PTX serum induced a similar decrease in P450 as obtained with CRF serum. Finally, PTX prevented the decrease of liver P450 in rats with CRF. In summary, PTH is the major mediator implicated in the downregulation of liver P450 in rats with CRF.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17021269     DOI: 10.1681/ASN.2006010035

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  18 in total

1.  Downregulation of hepatic acetylation of drugs in chronic renal failure.

Authors:  Emilie Simard; Judith Naud; Josée Michaud; Francois A Leblond; Alain Bonnardeaux; Chantal Guillemette; Edith Sim; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2008-04-16       Impact factor: 10.121

2.  Reduced hepatic synthesis of calcidiol in uremia.

Authors:  Josée Michaud; Judith Naud; Denis Ouimet; Christian Demers; Jean-Luc Petit; Francois A Leblond; Alain Bonnardeaux; Marielle Gascon-Barré; Vincent Pichette
Journal:  J Am Soc Nephrol       Date:  2010-07-01       Impact factor: 10.121

Review 3.  Consequences of renal failure on non-renal clearance of drugs.

Authors:  Laure Lalande; Bruno Charpiat; Gilles Leboucher; Michel Tod
Journal:  Clin Pharmacokinet       Date:  2014-06       Impact factor: 6.447

4.  Conversion of oral alfacalcidol to oral calcitriol in the treatment of secondary hyperparathyroidism in chronic hemodialysis patients.

Authors:  Sandrine Rauscher; Jean-Philippe Lafrance; Vincent Pichette; Robert Z Bell; Katherine Desforges; Laurence Lepage; Georges Ouellet; Denis Ouimet; Martine Leblanc; Caroline Lamarche; Sarah Bezzaoucha; Michel Vallee
Journal:  Int Urol Nephrol       Date:  2016-11-08       Impact factor: 2.370

5.  Warfarin dosing in patients with impaired kidney function.

Authors:  Nita A Limdi; Mohit A Limdi; Larisa Cavallari; Aaron M Anderson; Michael R Crowley; Melissa F Baird; Michael Allon; T Mark Beasley
Journal:  Am J Kidney Dis       Date:  2010-08-14       Impact factor: 8.860

6.  Phase I trial of rosiglitazone in FSGS: I. Report of the FONT Study Group.

Authors:  Melanie S Joy; Debbie S Gipson; Mary Dike; Leslie Powell; Amber Thompson; Suzanne Vento; Allison Eddy; Agnes B Fogo; Jeffrey B Kopp; Daniel Cattran; Howard Trachtman
Journal:  Clin J Am Soc Nephrol       Date:  2008-12-10       Impact factor: 8.237

7.  Hepatic clearance, but not gut availability, of erythromycin is altered in patients with end-stage renal disease.

Authors:  H Sun; L A Frassetto; Y Huang; L Z Benet
Journal:  Clin Pharmacol Ther       Date:  2010-01-20       Impact factor: 6.875

8.  CYP3A5 polymorphism affects the increase in CYP3A activity after living kidney transplantation in patients with end stage renal disease.

Authors:  Yosuke Suzuki; Takashi Fujioka; Fuminori Sato; Kunihiro Matsumoto; Nanako Muraya; Ryota Tanaka; Yuhki Sato; Keiko Ohno; Hiromitsu Mimata; Satoshi Kishino; Hiroki Itoh
Journal:  Br J Clin Pharmacol       Date:  2015-10-03       Impact factor: 4.335

Review 9.  The effect of chronic renal failure on drug metabolism and transport.

Authors:  Albert W Dreisbach; Juan J L Lertora
Journal:  Expert Opin Drug Metab Toxicol       Date:  2008-08       Impact factor: 4.481

10.  Pharmacokinetics of mycophenolic acid in patients with lupus nephritis.

Authors:  Melanie S Joy; Tandrea Hilliard; Yichun Hu; Susan L Hogan; Mary Anne Dooley; Ronald J Falk; Philip C Smith
Journal:  Pharmacotherapy       Date:  2009-01       Impact factor: 4.705

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.